



*designed by nature,
delivered by science*

Company Profile

URL: <http://www.phyteau.co>

Location: Santa Fe, NM USA

Founded: July 2017

Company Stage: Seed.

Preclinical pharma; Consumer product is market-ready

Personnel: 3 staff, 4 advisors

Co-Founders:

Dr. Stephen Pandol,
Prof. of Medicine, UCLA;
Director, Pancreatic research,
Cedars-Sinai Medical Center

Bonn Macy, ex-McKinsey &
Booz Allen; Founder/Director
Startup Santa Fe; 20+ yrs exp.

Financial information:

Capital sought: \$1.5m

Investment to date:
\$100,000 -- SOSV

RebelBio biotech accelerator
UK/Ireland

Growth-Train food accelerator
Denmark

Plug and Play accelerator
Silicon Valley, 2019

Contact:

Bonn Macy
bonn@phyteau.co
tel: 1-505-216-6250

Executive Summary

A completely safe, new class of incretin therapeutics for diabetes, obesity, metabolic syndrome, NAFLD and weight-loss.

Problem:

Diabetes, obesity, and prediabetes are now considered global epidemics

- **over 500 million diabetics**
- **600 million obese, and**
- **527 million prediabetics**
- **1.9 billion over-weight people**

They continue to grow at double digit rates, uncontained by existing treatments and approaches. No new first-line therapeutics for decades.

Solution: *Hack your Hormones*

Phyteau's safe, effective therapeutics:

- activate and leverage the natural metabolic hormone system
- trigger intestinal enteroendocrine cells to release therapeutic levels of key metabolic hormones, including: GLP-1, PYY and CCK
- control insulin release, blood sugar, appetite, food-intake & gastric emptying
- are affordable, first-in-class, first-line treatments for type 2 diabetes, prediabetes & weight management
- work entirely in the intestines, eliminating systemic side-effects

Our potential markets are huge

Diabetes & obesity drugs: \$35 billion--doubled from 2014 to 2020

Nutraceuticals: \$6 billion

Medical & Functional Foods: \$25 billion weight-loss, diabetic & fatty liver


Phyteau Go-to-Market Plan:

Enter consumer health markets now and generate revenue quickly, reinvesting earnings into pharma & consumer product development, reducing future capital raises & mitigating risk. **Next 18 months:**

- Produce product inventory for consumer market introduction/sales
- Build team, expand capabilities and capacity
- Sell product into our partner's healthcare providers referral network
- Aggressively introduce and market DTC consumer products
- Conduct human trials to validate product efficacy & market claims
- Introduce medical foods product for liver disease, NAFLD, NASH
- Continue product development, build out IP and patent portfolio
- Develop co-distribution & market initiatives in EU and China
- Complete preclinical work for pharmaceutical IND

Use of Funds:

\$1.5m capital sought



A stageable investment in:

- novel and patent-protected new products
- experience and efficiency
- low overheads
- market entry and validation
- scaleable operations

Financial Proforma (\$1000)

	yr 1	yr 2	yr 3
Revenues	\$339	\$3,253	\$9,644
Expenses	\$795	\$1,806	\$3,118
EBITDA	\$(574)	\$219	\$2,782

Selected as "Top 500 Deeptech Startups Worldwide" for 2019 by Hello Tomorrow